Uroplakin II Expression in Breast Carcinomas Showing Apocrine Differentiation: Putting Some Emphasis on Invasive Pleomorphic Lobular Carcinoma as a Potential Mimic of Urothelial Carcinoma at Metastatic Sites

Table 1

The detailed information of the antibodies used in the present study.

Antibodies to	Clone	Dilution	Pretreatment	Source
Uroplakin II	BC21	1 : 100	HIER	Biocare Medical, Concord, CA
GATA3	L50-823	1 : 100	HIER	Biocare Medical, Concord, CA
p40	BC28	1 : 100	HIER	Biocare Medical, Concord, CA
p63	4A4	1 : 100	HIER	Biocare Medical, Concord, CA
CK7	OV-TL 12/30	1 : 100	HIER	Dako, Glostrup, Denmark
CK20	Ks20.8	1 : 100	HIER	Dako, Glostrup, Denmark
34βE12	34βE12	1 : 100	HIER	Dako, Glostrup, Denmark
GCDFP-15	23A3	1 : 200	HIER	Dako, Glostrup, Denmark
E-cadherin	NCH-38	1 : 100	HIER	Dako, Glostrup, Denmark

GCDFP-15: gross cystic disease fluid protein-15; HIER: heat-induced epitope retrieval.